SIGNET RING CELL ADENOCARCINOMA
Clinical trials for SIGNET RING CELL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new SIGNET RING CELL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for SIGNET RING CELL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a Chemo-Immunotherapy combo outsmart resistant colorectal cancer?
Disease control OngoingThis phase 2 trial is testing whether adding the immunotherapy drug nivolumab (Opdivo) to standard chemotherapy (oxaliplatin, 5-fluorouracil, folinic acid) can help control or shrink a hard-to-treat type of metastatic colorectal cancer (pMMR/MSS). The study includes 80 adults who…
Matched conditions: SIGNET RING CELL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University Hospital, Akershus • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors
Disease control OngoingThis phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …
Matched conditions: SIGNET RING CELL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC